VERTEX PHARMACEUTICALS INC / MA Taxes Payable, Current
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Taxes Payable, Current of $103.10 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:TaxesPayableCurrent · last filed 2026-02-13
- 2025-12-31: Taxes Payable, Current $103.10M.
- 2024-12-31: Taxes Payable, Current $161.10M.
- 2023-12-31: Taxes Payable, Current $99.50M.
- 2022-12-31: Taxes Payable, Current $123.30M.
| Period end | Taxes Payable, Current | Taxes Payable, Current as first filed |
|---|---|---|
| 2025-12-31 | $103.10M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $161.10M 10-K · filed 2026-02-13 | |
| 2023-12-31 | $99.50M 10-K · filed 2025-02-13 | |
| 2022-12-31 | $123.30M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $211.30M 10-K · filed 2023-02-10 | |
| 2020-12-31 | $104.20M 10-K · filed 2022-02-09 | $104.17M 10-K · filed 2021-02-11 |
| 2019-12-31 | $72.29M 10-K · filed 2021-02-11 | |
| 2018-12-31 | $43.28M 10-K · filed 2020-02-13 | |
| 2014-12-31 | $14.21M 10-K · filed 2015-02-13 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 | |
| 2012-12-31 | $715.00K 10-K · filed 2014-02-11 | |
| 2012-09-30 | $3.87M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $201.00K 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $201.00K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $12.07M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $9.76M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $15.21M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |